{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:13:49Z","timestamp":1792192429321,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-019-03654-6","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:09:25Z","timestamp":1553677765000},"page":"1421-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis"],"prefix":"10.1007","volume":"98","author":[{"given":"T.","family":"Demuynck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"3","key":"3654_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","volume":"5","author":"AM Vannucchi","year":"2010","unstructured":"Vannucchi AM (2010) Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med 5(3):177\u2013184","journal-title":"Intern Emerg Med"},{"issue":"20","key":"3654_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"4","key":"3654_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, Olivares R, Igbal U, Mesa R (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92(4):289\u2013297","journal-title":"Eur J Haematol"},{"issue":"6","key":"3654_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24(6):1128\u20131138","journal-title":"Leukemia"},{"issue":"9","key":"3654_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E (2013) Finazzi Gea. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"issue":"10","key":"3654_CR6","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232","journal-title":"J Clin Oncol"},{"key":"3654_CR7","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 5:e366","journal-title":"Blood Cancer J"},{"issue":"2","key":"3654_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","volume":"34","author":"H Geyer","year":"2016","unstructured":"Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hern\u00e1ndez-Maraver D, D\u00f6hner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA (2016) Symptomatic profiles of patients with polycythemia Vera: implications of inadequately controlled disease. J Clin Oncol 34(2):151\u2013159","journal-title":"J Clin Oncol"},{"issue":"10","key":"3654_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ajh.24098","volume":"90","author":"LA Anderson","year":"2015","unstructured":"Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF (2015) Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol 90(10):864\u2013870","journal-title":"Am J Hematol"},{"key":"3654_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN landmark survey. BMC Cancer 16:167","journal-title":"BMC Cancer"},{"issue":"1","key":"3654_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, de Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333","journal-title":"N Engl J Med"},{"issue":"6","key":"3654_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129(6):680\u2013692","journal-title":"Blood"},{"issue":"3","key":"3654_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.13812","volume":"172","author":"MF McMullin","year":"2016","unstructured":"McMullin MF, Wilkins BS, Harrison CN (2016) Management of polycythaemia vera: a critical review of current data. Br J Haematol 172(3):337\u2013349","journal-title":"Br J Haematol"},{"issue":"5","key":"3654_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069","journal-title":"Leukemia"},{"issue":"6","key":"3654_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","volume":"94","author":"M Griesshammer","year":"2015","unstructured":"Griesshammer M, Gisslinger H, Mesa R (2015) Current and future treatment options for polycythemia vera. Ann Hematol 94(6):901\u2013910","journal-title":"Ann Hematol"},{"issue":"5","key":"3654_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11899-016-0311-8","volume":"11","author":"A Reiter","year":"2016","unstructured":"Reiter A, Harrison C (2016) How we identify and manage patients with inadequately controlled polycythemia Vera. Curr Hematol Malig Rep 11(5):356\u2013367","journal-title":"Curr Hematol Malig Rep"},{"issue":"29","key":"3654_CR17","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29(29):3907\u20133913","journal-title":"J Clin Oncol"},{"issue":"7","key":"3654_CR18","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, ECLAP Investigators (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664\u20132670","journal-title":"Blood"},{"issue":"5","key":"3654_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, de Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM, On behalf of the AGIMM Investigators (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol 87(5):552\u2013554","journal-title":"Am J Hematol"},{"issue":"6","key":"3654_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, Angona A, Gomez M, Muina B, Guillen H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363\u20131369","journal-title":"Blood"},{"issue":"5","key":"3654_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172(5):786\u2013793","journal-title":"Br J Haematol"},{"key":"3654_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","volume":"5","author":"S Parasuraman","year":"2015","unstructured":"Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ (2015) Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol 5:3","journal-title":"Exp Hematol Oncol"},{"key":"3654_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961\u2013963","journal-title":"Br J Haematol"},{"issue":"5","key":"3654_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435","journal-title":"N Engl J Med"},{"issue":"1","key":"3654_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399","journal-title":"Lancet Oncol"},{"key":"3654_CR26","doi-asserted-by":"publisher","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F et al (2015) Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1409002","DOI":"10.1056\/NEJMoa1409002"},{"issue":"3","key":"3654_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.22026","volume":"107","author":"RT Silver","year":"2006","unstructured":"Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107(3):451\u2013458","journal-title":"Cancer"},{"issue":"2","key":"3654_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/ejh.12707","volume":"97","author":"R Mesa","year":"2016","unstructured":"Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, C\u00f4t\u00e9 I, Habr D, Vannucchi AM (2016) Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol 97(2):192\u2013200","journal-title":"Eur J Haematol"},{"issue":"7","key":"3654_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101(7):821\u2013829","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03654-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03654-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03654-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:17:02Z","timestamp":1585181822000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03654-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3654"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03654-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Thomas Demuynck, Gregor Verhoef, Michel Delforge, and Peter Vandenberghe have no conflict of interest to declare. Timothy Devos did participate in an advisory board for Novartis and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}